Literature DB >> 18991770

Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D.

Yoshiro Chuman1, Hiroaki Yagi, Tomohiko Fukuda, Takao Nomura, Miho Matsukizono, Yasuyuki Shimohigashi, Kazuyasu Sakaguchi.   

Abstract

Protein phosphatase magnesium-dependent 1, delta (PPM1D) is a member of the PPM1 (formerly PP2C) protein phosphatase family, and is induced in response to DNA damage. The overexpression of PPM1D is thought to exert oncogenic effects through the inhibition of tumor suppressor proteins. PPM1D shows high selectivity for the primary sequence in its substrates when compared with other phosphatases, but the mechanisms underlying substrate recognition by this enzyme is not clearly known. In our present study we wished to identify the active center and further elucidate the substrate preference of PPM1D, and to this end performed sequence alignments among the human PPM1 type phosphatases. The results of this analysis clearly showed that the putative active site residues of PPM1D are highly conserved among the PPM1 family members. Phosphatase analyses using PPM1D mutants further identified the metal-chelating residues and a phosphate binding residue. In kinetic analyses using a series of phosphorylated p53 peptide analogs, the introduction of acidic residues into the region flanking the sites of dephosphorylation enhanced their affinity with PPM1D. Homology modeling of PPM1D also revealed that PPM1D contains two characteristic loops, a Pro-residue rich loop on the opposite side of the active site and a basic-residue rich loop in the vicinity of the active site in the catalytic domain. Interestingly, nonhydrolyzable AP4-3E peptides derived from the acidic p53 peptide analogs very effectively blocked PPM1D activity in an uncompetitive manner, suggesting that AP4-3E peptides may be useful lead compounds in the development of novel inhibitors of PPM1D.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991770     DOI: 10.2174/092986608785849236

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  9 in total

1.  Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.

Authors:  Aidan G Gilmartin; Thomas H Faitg; Mark Richter; Arthur Groy; Mark A Seefeld; Michael G Darcy; Xin Peng; Kelly Federowicz; Jingsong Yang; Shu-Yun Zhang; Elisabeth Minthorn; Jon-Paul Jaworski; Michael Schaber; Stan Martens; Dean E McNulty; Robert H Sinnamon; Hong Zhang; Robert B Kirkpatrick; Neysa Nevins; Guanglei Cui; Beth Pietrak; Elsie Diaz; Amber Jones; Martin Brandt; Benjamin Schwartz; Dirk A Heerding; Rakesh Kumar
Journal:  Nat Chem Biol       Date:  2014-01-05       Impact factor: 15.040

2.  Binding of a third metal ion by the human phosphatases PP2Cα and Wip1 is required for phosphatase activity.

Authors:  Kan Tanoue; Lisa M Miller Jenkins; Stewart R Durell; Subrata Debnath; Hiroyasu Sakai; Harichandra D Tagad; Kazushige Ishida; Ettore Appella; Sharlyn J Mazur
Journal:  Biochemistry       Date:  2013-08-16       Impact factor: 3.162

3.  Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).

Authors:  Ryo Hayashi; Kan Tanoue; Stewart R Durell; Deb K Chatterjee; Lisa M Miller Jenkins; Daniel H Appella; Ettore Appella
Journal:  Biochemistry       Date:  2011-05-09       Impact factor: 3.162

4.  Structurally diverse low molecular weight activators of the mammalian pre-mRNA 3' cleavage reaction.

Authors:  Min Ting Liu; Nagaraja N Nagre; Kevin Ryan
Journal:  Bioorg Med Chem       Date:  2013-12-15       Impact factor: 3.641

Review 5.  Metal dependent protein phosphatase PPM family in cardiac health and diseases.

Authors:  Chen Gao; Nancy Cao; Yibin Wang
Journal:  Cell Signal       Date:  2021-06-06       Impact factor: 4.850

6.  Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.

Authors:  Peter G Miller; Murugappan Sathappa; Jamie A Moroco; Wei Jiang; Yue Qian; Sumaiya Iqbal; Qi Guo; Andrew O Giacomelli; Subrata Shaw; Camille Vernier; Besnik Bajrami; Xiaoping Yang; Cerise Raffier; Adam S Sperling; Christopher J Gibson; Josephine Kahn; Cyrus Jin; Matthew Ranaghan; Alisha Caliman; Merissa Brousseau; Eric S Fischer; Robert Lintner; Federica Piccioni; Arthur J Campbell; David E Root; Colin W Garvie; Benjamin L Ebert
Journal:  Nat Commun       Date:  2022-06-30       Impact factor: 17.694

7.  Activation of WIP1 phosphatase by HTLV-1 Tax mitigates the cellular response to DNA damage.

Authors:  Tajhal Dayaram; Francene J Lemoine; Lawrence A Donehower; Susan J Marriott
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

8.  PPM1D controls nucleolar formation by up-regulating phosphorylation of nucleophosmin.

Authors:  Yuuki Kozakai; Rui Kamada; Junya Furuta; Yuhei Kiyota; Yoshiro Chuman; Kazuyasu Sakaguchi
Journal:  Sci Rep       Date:  2016-09-13       Impact factor: 4.379

Review 9.  WIP1 phosphatase as pharmacological target in cancer therapy.

Authors:  Soňa Pecháčková; Kamila Burdová; Libor Macurek
Journal:  J Mol Med (Berl)       Date:  2017-04-24       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.